The Top 5 Analyst Questions From Bruker's Q4 Earnings Call
Bruker (BRKR) faced a challenging Q4 2025 with ongoing weakness in U.S. academic and government funding, tariff pressures, and unfavorable currency movements, leading to an EPS miss though revenue beat estimates. Analysts questioned management on the sustainability of cost reductions, confidence in margin expansion, growth assumptions across markets, backlog trends, and Q1 revenue expectations, to which the company provided detailed responses outlining future strategies and market outlook. Key catalysts for upcoming quarters include monitoring cost-saving realization, sustained order momentum, and stabilization in U.S. funding.
Bruker Corp (BRKR) Shares Up 3.12% on Feb 17
Bruker Corp (BRKR) shares rose 3.12% on February 17, closing at $37.65, putting it 33.03% below its 52-week high and 31.97% above its 52-week low. Wall Street analysts predict an average one-year price target of $48.95, suggesting a 30.02% upside, and an "Outperform" recommendation. GuruFocus estimates a fair value of $73.38, indicating a potential 94.9% upside.
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down
Bruker Corporation (BRKR) reported Q4 2025 adjusted earnings that missed analyst estimates by 9.2%, falling 22.4% year over year, despite revenues slightly beating expectations. The company experienced contracting gross and operating margins due to lower volume, unfavorable mix, tariffs, and currency headwinds. Bruker provided 2026 guidance, projecting revenue growth of 4% to 5% and adjusted EPS growth of 15% to 17%.
US$48.43: That's What Analysts Think Bruker Corporation (NASDAQ:BRKR) Is Worth After Its Latest Results
Following Bruker Corporation's latest annual results, analysts have updated their forecasts, leading to a considerable shift in sentiment. Despite revenues aligning with expectations at US$3.4 billion, projected losses per share for 2026 have increased significantly to US$2.15, overturning previous profit predictions. Consequently, the consensus price target has been lowered by 11% to US$48.43, reflecting concerns over ongoing losses and a slower projected revenue growth rate compared to the industry.
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $35 to $49
Major Wall Street analysts have updated their ratings for Bruker Corp (BRKR.US) on February 14th, with price targets ranging from $35 to $49. Goldman Sachs initiated coverage with a sell rating at $35, while BofA Securities maintained a buy rating, adjusting its target to $49. Other analysts from Citi, UBS, and TD Cowen maintained hold ratings with revised or maintained target prices.
Bruker (BRKR) Price Target Lowered by Citigroup, Rating Maintained | BRKR Stock News
Citigroup analyst Patrick Donnelly has lowered the price target for Bruker (BRKR) from $53.00 to $40.00, while maintaining a 'Neutral' rating on the stock. Despite this reduction, other analysts have recently raised their price targets for Bruker, and the average target price from 16 analysts suggests a 43.97% upside from its current price. GuruFocus estimates a one-year fair value of $74.37 for BRKR, indicating a potential upside of 104.37%.
These Analysts Cut Their Forecasts On Bruker Following Q4 Results
Bruker (NASDAQ: BRKR) reported mixed Q4 financial results, with earnings missing analyst estimates but sales exceeding expectations. Following the report, two analysts, Luke Sergott from Barclays and Dan Brennan from TD Cowen, lowered their price targets on Bruker shares. The company provided its outlook for FY2026 adjusted EPS and sales, with the sales forecast beating current estimates.
Bruker Corporation (NASDAQ:BRKR) Q4 2025 Earnings Call Transcript
Bruker Corporation (NASDAQ:BRKR) reported its Q4 2025 earnings, with revenues ahead of expectations but missing EPS estimates due to various headwinds including tariffs and currency. The company provided a full-year 2026 financial outlook, anticipating 4% to 5% reported revenue growth and significant non-GAAP operating profit margin expansion. Bruker expects a return to organic revenue growth in Q2 2026 after a projected decline in Q1, driven by improving market conditions, cost-saving initiatives, and strong order momentum in several end markets.
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $40 to $53
Several Wall Street analysts updated their ratings for Bruker Corp (BRKR.US) on February 13, 2026, setting price targets between $40 and $53. Analyst ratings include one hold and three buy recommendations, with adjusted target prices reflecting a range of expert opinions on the stock's future performance.
BRUKER ($BRKR) Releases Q4 2025 Earnings
Bruker ($BRKR) reported its Q4 2025 earnings, missing analyst estimates for both earnings per share and revenue. The company reported earnings of $0.59 per share against an estimated $0.66, and revenue of $977.2 million compared to an estimated $980.05 million. The article also provides details on insider trading activity, hedge fund movements, government contracts, and analyst ratings for BRKR.
Bruker Shares Tumble on Q4 Earnings Miss and Weaker Margins Despite 2026 Growth Outlook
Bruker Corporation's shares fell sharply after missing Q4 earnings expectations and reporting weaker margins. The company's Q4 revenues were flat year-over-year, and adjusted EPS declined, attributed to cost pressures and volume weakness. Despite a challenging 2025, Bruker provided 2026 guidance targeting revenue growth and double-digit earnings growth, expecting improved demand later in the year, particularly in biopharma and industrial research.
Bruker: Q4 Earnings Snapshot
Bruker Corp. (BRKR) reported Q4 net income of $26 million, or 10 cents per share, missing analyst expectations with adjusted earnings of 59 cents per share against an average estimate of 65 cents. The company posted Q4 revenue of $977.2 million and a full-year loss of $8.6 million, or 15 cents per share, on revenue of $3.44 billion. Bruker forecasts full-year earnings between $2.10 and $2.15 per share and revenue between $3.57 billion and $3.6 billion.
Why Bruker (BRKR) Stock Is Trading Lower Today
Bruker (BRKR) stock is trading lower after the company reported disappointing fourth-quarter 2025 financial results, including an earnings miss and a 22.4% decrease from the previous year. While revenue was flat year-over-year, it declined organically, and the full-year adjusted earnings guidance for 2026 fell short of analyst estimates. This news continues a trend of volatility for Bruker, which also announced a weak organic revenue growth forecast for 2026 a month prior.
Earnings call transcript: Bruker Q4 2025 earnings miss, stock drops 14%
Bruker Corporation reported its Q4 2025 earnings, missing EPS expectations by 9.23% with $0.59 against a forecast of $0.65, causing its stock to drop 14.05% in pre-market trading. Despite this, the company's revenue of $977.2 million surpassed the forecast of $959.08 million. Bruker anticipates revenue growth of 1% to 2% for 2026 and robust non-GAAP EPS growth of 15% to 17%, driven by cost-saving initiatives expected to exceed $140 million.
Bruker: Q4 Financial Results Overview
Bruker Corp. reported Q4 net profit of $26 million ($0.10 per share) and adjusted earnings of $0.59 per share, missing analyst expectations of $0.65 per share. The scientific instrument manufacturer generated $977.2 million in revenue for the quarter. For the full year, Bruker had a net loss of $8.6 million on $3.44 billion in revenue and projects 2026 earnings to be between $2.10 and $2.15 per share with revenue of $3.57 billion to $3.6 billion.
Bruker Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Bruker Corporation announced its Q4 and full-year 2025 financial results, reporting revenues of $977.2 million for Q4 and $3.44 billion for the full year amidst challenging market conditions. Despite a slight revenue decrease in Q4, the company exceeded expectations and plans to extend cost-savings initiatives to drive significant operating margin expansion and double-digit EPS growth in 2026. Bruker has also provided a positive outlook for fiscal year 2026, forecasting revenues between $3.57 billion and $3.60 billion and strong non-GAAP EPS growth.
Bruker: Q4 Earnings Snapshot
Bruker Corp. reported a fourth-quarter net income of $26 million, or 10 cents per share, missing Wall Street expectations. The scientific equipment maker posted revenue of $977.2 million for the quarter and a full-year loss of $8.6 million on $3.44 billion in revenue. Bruker's shares have seen a significant decrease since the beginning of the year and over the last 12 months.
Bruker: Q4 Financial Results Overview
Bruker Corp. reported a net profit of $26 million ($0.10 per share) for Q4, with adjusted earnings of $0.59 per share, missing analyst expectations of $0.65 per share. The company generated $977.2 million in revenue for the quarter and a net loss of $8.6 million for the full year. Bruker projects full-year earnings between $2.10 and $2.15 per share, with revenue between $3.57 billion and $3.6 billion.
Bruker (BRKR) Launches iNTApharma for Advanced Bioparticle Analysis
Bruker Corporation (BRKR) has launched iNTApharma, a new platform for label-free nanoscale bioparticle analysis, at the SLAS 2026 conference. This technology allows for rapid size and concentration assessments of bioparticles in their native state, crucial for research and therapy development. Despite this innovation, Bruker faces challenges in profitability with a negative net margin, though its balance sheet shows moderate leverage and a positive Beneish M-Score indicating low manipulation risk.
New Bruker tool speeds mRNA and gene therapy nanoparticle checks
Bruker Corporation has launched iNTApharma™, a label-free platform designed to quickly and accurately characterize nanoparticles used in mRNA drug and gene therapy development and quality control. This new system offers single-particle sensitivity for size and concentration measurements in native aqueous media, addressing the growing need for precise, native-state analysis of viral vectors, lipid nanoparticles, and extracellular vesicles. The iNTApharma platform is optimized for bioparticles between 50 and 300 nanometers and enables automated analysis of diverse biological samples.
Old West Investment Management LLC Buys 338,618 Shares of Bruker Corporation $BRKR
Old West Investment Management LLC significantly increased its stake in Bruker Corporation (NASDAQ:BRKR) by 144.2% in the third quarter, purchasing an additional 338,618 shares. Following this acquisition, Bruker now constitutes 4.3% of Old West's investment portfolio, making it their fourth-largest holding. Institutional investors collectively own 79.52% of Bruker's stock, while company insiders hold 27.30%.
Investors get Feb. 12 date for Bruker Q4 2025 earnings call
Bruker Corporation (Nasdaq: BRKR) has announced that it will release its fourth quarter and fiscal year 2025 financial results before market opening on Thursday, February 12, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss these results and current business trends. Investors can access the webcast via the company's investor relations website or by telephone registration.
Bruker to pay $3.9844 per share to preferred holders Mar. 2
Bruker Corporation announced a quarterly cash dividend of $3.9844 per share for its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend will be paid on March 2, 2026, to stockholders of record as of February 15, 2026. This announcement highlights Bruker's regular dividend distribution to its preferred shareholders.
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
Analysts are predicting a year-over-year decline in Bruker's (BRKR) earnings and revenues for the quarter ended December 2025, with an estimated EPS of $0.65 per share and revenues of $966.4 million. The Zacks Consensus Estimate for EPS has been revised 9.84% lower over the last 30 days. Despite the company beating EPS estimates in three of the last four quarters, Bruker currently has a Zacks Earnings ESP of 0% and a Zacks Rank of #3, making a definitive earnings beat difficult to predict.
Barclays Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $55
Barclays analyst Luke Sergott has maintained a Buy rating on Bruker Corp (BRKR.US) and kept the target price at $55. Data from TipRanks indicates that Sergott has a 45.6% success rate and an average return of -0.2% over the past year. The information provided is for educational purposes and is not investment advice.
Guggenheim Raises Price Target for Bruker Corporation (BRKR)
Guggenheim analyst Subbu Nambi reiterated a "Buy" rating for Bruker Corporation (BRKR) and raised its price target from $53 to $58, indicating a potential upside of 25%. This adjustment is part of Guggenheim's broader revisions within the Diagnostics and Life Sciences Tools sector, based on recent updates and preliminary Q4 results. This follows a reaffirmation of a "Hold" rating from TD Cowen's Daniel Brennan on January 7, who also revised his price target to $53.
Guggenheim Raises Price Target for Bruker Corporation (BRKR)
Guggenheim analyst Subbu Nambi reiterated a "Buy" rating for Bruker Corporation (BRKR) and raised the price target from $53 to $58, indicating a potential 25% upside. This adjustment is based on updated forecasts for the Diagnostics and Life Sciences Tools sector. Separately, TD Cowen analyst Daniel Brennan reaffirmed a "Hold" rating, adjusting his price target from $42 to $53, citing a soft guidance for 2026 which offers optimism for the coming year.
Guggenheim Raises Price Target for Bruker Corporation (BRKR)
Guggenheim analyst Subbu Nambi raised her price target for Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and indicating a nearly 25% upside potential. This revision is based on recent updates and preliminary Q4 results, following similar adjustments by TD Cowen's Daniel Brennan, who reaffirmed a Hold rating but increased his price target to $53. Bruker Corporation develops and distributes high-performance scientific instruments and analytical solutions across various fields.
Eclipse Bioinnovations, Inc. acquired Terrain Biosciences, Inc. from Magnetic Ventures and Bruker Corporation.
Eclipse Bioinnovations, Inc. has acquired Terrain Biosciences, Inc. from Magnetic Ventures and Bruker Corporation. The acquisition was completed on January 26, 2026, and EclipseBio plans to continue supporting existing Terrain Bio customers and collaborate with partners for a smooth transition. Bruker Corporation's stock performance and other recent news, including various acquisitions and financial announcements, are also mentioned in the article.
Guggenheim Maintains Bruker Corp(BRKR.US) With Buy Rating, Raises Target Price to $58
Guggenheim analyst Subbu Nambi has reiterated a buy rating for Bruker Corp (BRKR.US) and increased the target price from $53 to $58. According to TipRanks, the analyst has a 75.3% success rate and a 37.1% average return over the past year. The information provided is for informational purposes only and does not constitute investment advice.
Stocks To Watch: Bruker Sees Relative Strength Rating Rise To 82
Bruker (BRKR) has seen its Relative Strength (RS) Rating increase from 78 to 82, reaching a key benchmark for market leadership. The RS Rating is a proprietary metric that tracks a stock's price performance over 52 weeks, with scores of 80 or higher indicating strong leadership. This marks another instance of Bruker achieving an elevated RS Rating.
Bruker Corporation (BRKR): A Bull Case Theory
This article summarizes a bullish thesis on Bruker Corporation (BRKR), highlighting its leadership in advanced scientific instrumentation and spatial biology. Despite recent macro headwinds and stock volatility, the company remains financially strong with resilient earnings and significant growth potential in its core technologies. The analysis suggests BRKR is undervalued with a realistic valuation much higher than its current market cap.
SG Americas Securities LLC Has $1.37 Million Stake in Bruker Corporation $BRKR
SG Americas Securities LLC significantly increased its stake in Bruker Corporation (NASDAQ:BRKR) by 199.8% in Q3, now holding 42,293 shares worth approximately $1.37 million. Institutional investors collectively own about 79.52% of the company. Despite analyst upgrades and raised price targets, the consensus rating for Bruker remains a "Hold" with a target price of $53.36, while the company reported strong Q3 earnings, beating estimates and providing a positive FY25 EPS guidance, although insiders have recently sold shares.
Bruker (NASDAQ:BRKR) VP Sells $98,400.00 in Stock
Bruker (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the company's stock for $98,400 on January 15th, following a prior sale of 7,000 shares on January 12th. This transaction reduced his position by 1.53%. Bruker's stock experienced a 2.2% drop to $48.39, while the company recently exceeded quarterly EPS and revenue expectations and provided positive FY2025 guidance.
September 18th Options Now Available For Bruker (BRKR)
New options contracts for Bruker Corp (BRKR) with a September 18th expiration are now available. The article highlights a put contract at the $45.00 strike price and a call contract at the $52.50 strike price, analyzing their potential for premium collection and YieldBoost returns for investors. It discusses strategies like selling-to-open puts to potentially acquire shares at a discount or covered calls to generate income.
Bruker Teases 2026 Margin Surge, $120M Cost Cuts and Double-Digit EPS Growth After Rough 2025
Bruker (NASDAQ: BRKR) is targeting significant profitability improvements in 2026 after a challenging 2025, aiming for 250–300 basis points of organic operating margin expansion, multi-year margin growth into the low/mid-20s, and double-digit non-GAAP EPS growth. These goals are supported by $120 million in planned cost savings and an increased focus on recurring, high-margin revenue through its "Project Accelerate 3.0" initiative, particularly in clinical microbiology and molecular diagnostics. The company is also banking on product innovation in spatial biology and new mass-spec systems to drive future growth.
Bruker (BRKR) Projects Modest Revenue Growth and EPS Increase fo
Bruker (BRKR) has projected modest organic revenue growth and significant improvements in operating margins and EPS for 2026. The company, which operates in the medical devices and instruments industry, anticipates a double-digit boost in non-GAAP earnings per share. Despite a solid 3-year revenue growth rate, Bruker faces challenges in profitability and efficiency, as indicated by a negative net margin and a high RSI suggesting overbought conditions.
BofA Securities Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $60
BofA Securities analyst Michael Ryskin has reiterated a Buy rating for Bruker Corp (BRKR.US) and maintained a target price of $60. According to TipRanks data, the analyst has a 56.2% success rate and a 4.4% average return over the past year. This information is provided for educational purposes and should not be considered investment advice.
Bruker Teases 2026 Margin Surge, $120M Cost Cuts and Double-Digit EPS Growth After Rough 2025
Bruker (NASDAQ:BRKR) executives presented an "incremental evolutionary" update for 2026, targeting significant profitability improvement, including a 250-300 basis point organic operating margin expansion and double-digit non-GAAP EPS growth, supported by $120 million in cost savings. The company plans to shift towards recurring, high-margin revenue through its expanded Project Accelerate 3.0, focusing on clinical microbiology and molecular diagnostics, product innovation in spatial biology and mass spectrometry, and semiconductor metrology. This strategic pivot follows a "rough" 2025, during which the company faced headwinds from weak academic demand, industrial and biopharma research spending hesitation, and tariff/currency volatility.
Why Bruker (BRKR) Shares Are Plunging Today
Shares of scientific instrument company Bruker (BRKR) fell 6.4% after the company provided a weak organic revenue growth forecast for 2026, expecting flat to low-single-digit growth following a challenging 2025. Despite projections for double-digit non-GAAP earnings per share growth and expanded operating margins in 2026, investors focused on the sluggish revenue outlook, causing a negative market reaction. Bruker’s shares have been volatile, and this move indicates the market views the news as meaningful.
Bruker Corp (BRKR) Shares Down 6.48% on Jan 13
Bruker Corp (BRKR) shares dropped 6.48% on January 13, trading at $49.95 after reaching an intraday low of $49.82. Wall Street analysts have an average target price of $53.14 for BRKR, with a consensus "Outperform" recommendation. GuruFocus estimates the fair value (GF Value) at $74.08, suggesting a significant upside.
Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI
Bruker's BEST division has secured two multi-year supply agreements totaling approximately $500 million for its high-performance superconductors, essential components for next-generation MRI magnets. These expanded agreements with global healthcare companies underscore confidence in Bruker's superconductor technology, particularly for novel helium-free MRI systems. The agreements ensure continued partnerships and stability for Bruker's superconductor business, highlighting its role in advancing MRI and other deep-tech superconductivity applications.
Bruker lands big deal to supply MRI tech that cuts helium use
Bruker's Energy & Supercon Technologies (BEST) division has secured two multi-year supply agreements totaling approximately $500 million for its high-performance superconductors. These superconductors are crucial for the next generation of MRI magnets, including those in helium-free systems, and will be supplied to global radiology companies. The deals, which expand previous agreements, underscore confidence in Bruker's superconductivity innovation and supply chain, addressing the growing demand for more sustainable and cost-effective MRI technology.
Bruker acquires additional 60% stake in Tofwerk, terms undisclosed
Bruker (BRKR) has acquired an additional 60% ownership stake in Tofwerk, a company specializing in TOF-MS technology. This acquisition expands Bruker's reach into markets like atmospheric chemistry, air quality monitoring, and semiconductor cleanroom monitoring. Tofwerk, with over 1,000 instruments globally and 2025 revenues of approximately $40M, will continue to operate as a distinct brand within Bruker, though the financial terms of the deal were not disclosed.
Bruker secures $500 million in superconductor supply deals for MRI systems
Bruker Corporation has secured two multi-year supply agreements totaling approximately $500 million for its advanced superconductors, which are used in next-generation MRI magnets. These agreements, primarily for MRI magnet production sites in the US and UK, involve materials manufactured at Bruker's European and US facilities. The company anticipates a return to profitability this year, with analysts predicting growth in net income.
Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI (2026-01-09)
Bruker Energy & Supercon Technologies (BEST), a division of Bruker Corporation, has secured two multi-year supply agreements totaling approximately $500 million for its high-performance superconductors. These superconductors are critical components for next-generation MRI magnets used by global radiology companies. The agreements highlight the confidence of major OEM customers in Bruker's superconductor innovation and manufacturing capabilities, particularly for novel helium-free MRI magnet architectures.
Bruker acquires remaining 60% stake in TOFWERK for full ownership By Investing.com
Bruker Corporation has acquired the remaining 60% stake in TOFWERK AG, making it a wholly-owned subsidiary. TOFWERK, specializing in ultra-fast time-of-flight mass spectrometry, will operate as a distinct brand within Bruker. This acquisition expands Bruker's presence in small-molecule applied market segments, including atmospheric chemistry, air quality monitoring, and semiconductor cleanroom monitoring.
Bruker deal expands TOF tech for cleaner air and semiconductor cleanrooms
Bruker Corporation has fully acquired TOFWERK AG, an innovator in ultra-fast time-of-flight (TOF) mass spectrometry, consolidating its ownership to 100%. This acquisition expands Bruker's portfolio into new applied markets such as atmospheric chemistry research, air quality monitoring, and semiconductor cleanroom monitoring. TOFWERK, headquartered in Switzerland, will continue as a distinct brand within Bruker and is expected to generate approximately $40 million in revenue in 2025.
Bruker Corporation to Present at the J.P. Morgan Healthcare Conference
Bruker Corporation announced its participation in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on January 12, 2026, at 9:00 AM PST, with a live audio webcast and a replay available on the company's Investor Relations website. Bruker, a leader in the post-genomic era, focuses on high-performance scientific instruments and analytical solutions for life science, diagnostics, and various industrial applications.
How to listen in as Bruker joins J.P. Morgan's big health event
Bruker Corporation announced its participation in the 45th annual J.P. Morgan Healthcare Conference, where senior leadership will present on January 12th, 2026, at 9:00 AM Pacific Standard Time. A live audio webcast and a replay will be available on the company's Investor Relations website. Bruker, a leader in post-genomic discoveries, provides high-performance scientific instruments and analytical solutions to improve human life quality.
